argenx SE American Depositary Shares (ARGX)

Pharmaceutical company argenx reported positive phase 3 clinical trial results for VYVGART in treating generalized myasthenia gravis (gMG) patients who are AChR-Ab seronegative, demonstrating statistically significant improvements across multiple patient subtypes.

Argenx's drug Vyvgart demonstrated sustained disease control and improved functional and quality of life scores in patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, with a favorable safety profile.

Belgian stocks closed higher on Monday, with the BEL 20 index rising 1.37%. The top performers were Galapagos NV, UCB SA, and D'Ieteren NV, while Proximus NV, Aperam SA, and Argen-X declined.

Cartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.

These five biotech companies could have a lot of room to run.